Erasca, Inc.
NASDAQ:ERASBiotechnology
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
Volume 8.94M
Average 6.79M
ERAS EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Erasca, Inc.NASDAQ: ERAS
EPS (Basic) · Q3 FY2026 · quarter ended Sep 2026
EPS (Basic) remains negative
Q3 FY2026 EPS (Basic) was -$0.15, compared with -$0.11 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.99.
Context
- EPS (Basic) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 8 analysts of -$0.95 (-114.9%) for the fiscal year ending Dec 2026, a slowdown from the +36.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$0.15-7.1% QoQ
- Last fiscal yearDec 2025
- -$0.44+36.2% YoY
- LTMSep 2026
- -$0.99-120.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -36.4% | -29.3% | +7.0 pp |
| 1 year | +36.2% | -114.9% | -151.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (0.44) USD
- Year-over-year change
- +36.2%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.44) | +36.2% |
| FY2024 | 2024-12-31 | (0.69) | +16.9% |
| FY2023 | 2023-12-31 | (0.83) | +58.3% |
| FY2022 | 2022-12-31 | (1.99) | -93.2% |
| FY2021 | 2021-12-31 | (1.03) | — |
EPS (Basic) vs competitors
How ERAS compares with its peers on the latest reported figures
- ERAS's LTM Sep 2026 EPS (Basic) of -$0.99 is the 2nd highest of the 9 companies compared; the peer median is -$2.04.
- Its year-over-year change of -120.0% is the lowest of 9, against a peer median of +14.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | -$0.43 | +31.0% | — | |
| LTM Sep 2026 | -$0.99 | -120.0% | — | |
| LTM Sep 2026 | -$1.38 | -51.6% | — | |
| LTM Mar 2026 | -$1.44 | +23.0% | — | |
| LTM Mar 2026 | -$1.58 | +56.0% | — | |
| LTM Mar 2026 | -$2.5 | +30.0% | — | |
| LTM Mar 2026 | -$3.35 | -59.5% | — | |
| LTM Mar 2026 | -$3.53 | +6.4% | — | |
| LTM Jun 2026 | -$8.86 | -96.5% | — | |
| Peer median (excluding ERAS) | -$2.04 | +14.7% | — | |
Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 829K | 2.64M | 3.73M | 0 | 3.11M |
| Gross Profit | (829K) | (2.64M) | (3.73M) | 0 | (3.11M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 73.92M | 112.46M | 103.82M | 115.36M | 92.85M |
| Selling, General & Admin | 22.62M | 32.99M | 37.7M | 41.73M | 38.55M |
| Operating Expenses | 124.05M | 244.81M | 137.79M | 179.59M | 128.3M |
| Depreciation & Amortization | 829K | 2.64M | 3.73M | 3.81M | 3.11M |
| EBITDA | (121.94M) | (240.16M) | (121.31M) | (153.28M) | (121.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (124.88M) | (247.45M) | (141.53M) | (179.59M) | (131.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 190K | 4.9M | 16.71M | 20.09M | 16.61M |
| Interest Expense | 0 | 201.36M | 0 | 0 | 0 |
| Other Income / Expenses | 2.12M | 4.65M | 16.48M | 17.94M | 6.86M |
| Income Before Tax | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (122.76M) | (242.81M) | (125.04M) | (161.65M) | (124.55M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| EPS (Diluted) | (1.03) | (1.99) | (0.83) | (0.69) | (0.44) |
| Weighted Avg Shares | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M |
| Weighted Avg Shares (Diluted) | 119.1M | 122.02M | 150.18M | 233.82M | 283.53M |
Erasca, Inc.
NASDAQ:ERAS
Intrinsic Alpha fair value
Locked
Current Price
$13.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.